The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.

The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...

At its annual sellers’ conference, hosted in Seattle this week, Amazon continually told the thousands of independent vendors ...

Health-care company stocks fell as U.S. regulators look to crack down on prices and companies battle over market share of popular drugs. The Federal Trade Commission sued the drug middlemen that ...

Nike spent nearly $104 million on pay and benefits for John Donahoe during his near five-year tenure atop the sneaker-maker, ...

The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for diabetic patients. Three companies that ...

The United States Eighth Circuit Court of Appeals ruled that legal challenges to the Horseracing Integrity and Safety Act ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

In the second quarter, federal and state antitrust enforcers continued their intense scrutiny of consolidation in the healthcare market ...

Recently, the idea of reviving government price controls on food and other consumer staples has been injected into the public ...

FTC's action today is likely only the tip of the iceberg of necessary reforms to end PBMs' harmful business practices that have directly led to the lights going out for thousands of independent ...

The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.